Segulah Medical Acceleration
VC Fund
Stockholm, Sweden
Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Segulah Medical Acceleration invests in
Stages Segulah Medical Acceleration invests in
Countries Segulah Medical Acceleration invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $8.5M–$12M
- Series D
- $34M–$245M
Investment Focus
Industry
- Health Care 8 (89%)
- Medical Device 5 (56%)
- Biotechnology 3 (33%)
- Medical 2 (22%)
- Health Diagnostics 2 (22%)
Stage
- Series D 3 (33%)
- Series A 2 (22%)
- Seed 1 (11%)
- Series B 1 (11%)
- Funding Round 1 (11%)
Country
- Sweden 4 (44%)
- United Kingdom 3 (33%)
- Germany 1 (11%)
- United States 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gabriel Urwitz
Co-Founder
|
Co-Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Protembis
|
ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation. | $32.5M / Series B / Mar 26, 2024 | |
Collective Minds
|
Collective Minds® is the new radiology workspace. A cloud-based service for collaboration, consultation and access to new digital tools and expertise. We are building the largest global network of collective and artificial intelligence, with humans and machines. | $7.7M / Aug 28, 2023 | |
Navinci Diagnostics
|
Navinci Diagnostics is a company that develops proprietary technology for detecting and quantifying proteins, protein interactions, and protein modifications. | $8.5M / Series A / Jul 12, 2022 | |
Signifier Medical Technologies
|
Snoozeal was founded in 2015 in United Kingdom. Co-founder Prof. Dr Anshul Sama, working in a multidisciplinary sleep team, was deeply empathic with many of his patients that were struggling with conventional treatment options that had failed to change in the last two decades. Not dissimilar to practice in many parts of conventional medicine, theemphasis was on treatment of the end result (i.e. splinting the airway open) rather than treating the root cause- collapse of airway due to excessive loss of muscle tone. Over the years Prof Sama came across many devices, all of which had to be worn during sleep, were invariably uncomfortable, only effective when in use and further disrupted the already poor sleep quality. | $35M / Series D / Jul 27, 2021 | |
Allurion Technologies
|
Allurion Technologies is developing a medical device for weight loss that can be delivered and removed without surgery or endoscopy. | $34M / Series D / Jul 01, 2021 | |
SAGA Diagnostics
|
SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine,provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits.The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity. | $12.4M / Series A / Jun 29, 2021 | |
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $245M / Series D / Jun 23, 2021 | |
CytaCoat
|
CytaCoat is developing a new technology of antibacterial coating for medical devices. CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and theRoyal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that their proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses.CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses. | Venture - Series Unknown / Oct 01, 2020 | |
Vidya Health
|
Vidya Health is the medical technology company based in London | Seed / Sep 01, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Segulah Medical Acceleration invest in?
Segulah Medical Acceleration invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series D and Series A stage. Most of the 9 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Segulah Medical Acceleration's check size?
Segulah Medical Acceleration typically joins rounds of $8.5M–$12M at Series A and $34M–$245M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Segulah Medical Acceleration participates in.
How do I contact Segulah Medical Acceleration?
Public channels for Segulah Medical Acceleration include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Segulah Medical Acceleration?
The team at Segulah Medical Acceleration includes Gabriel Urwitz (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
